The finding that HDAC6 deficiency or inhibition suppressed the accumulation of both wild type FGFR3 and mutant activated FGFR3 [18] led to studies performed here that tested the effectiveness of tubacin and HDAC6 inhibition as a therapeutic strategy in FGFR3-dependent cancers. The gene discussed is FGFR3; the disease is cancer.